Annual Accounts Receivable
$27.52 M
-$9.09 M-24.83%
December 31, 2024
Summary
- As of March 12, 2025, PACB annual accounts receivable is $27.52 million, with the most recent change of -$9.09 million (-24.83%) on December 31, 2024.
- During the last 3 years, PACB annual accounts receivable has risen by +$3.28 million (+13.54%).
- PACB annual accounts receivable is now -24.83% below its all-time high of $36.62 million, reached on December 31, 2023.
Performance
PACB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$27.52 M
-$1.86 M-6.33%
December 31, 2024
Summary
- As of March 12, 2025, PACB quarterly accounts receivable is $27.52 million, with the most recent change of -$1.86 million (-6.33%) on December 31, 2024.
- Over the past year, PACB quarterly accounts receivable has dropped by -$1.86 million (-6.33%).
- PACB quarterly accounts receivable is now -24.83% below its all-time high of $36.62 million, reached on December 31, 2023.
Performance
PACB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PACB Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.8% | -6.3% |
| 3 y3 years | +13.5% | -6.3% |
| 5 y5 years | +80.3% | -6.3% |
PACB Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -24.8% | +46.5% | -24.8% | +46.5% |
| 5 y | 5-year | -24.8% | +80.3% | -24.8% | +275.8% |
| alltime | all time | -24.8% | -100.0% | -24.8% | -100.0% |
Pacific Biosciences Of California Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $27.52 M(-24.8%) | $27.52 M(-6.3%) |
| Sep 2024 | - | $29.38 M(-9.4%) |
| Jun 2024 | - | $32.43 M(+7.0%) |
| Mar 2024 | - | $30.32 M(-17.2%) |
| Dec 2023 | $36.62 M(+94.9%) | $36.62 M(+20.1%) |
| Sep 2023 | - | $30.49 M(+26.8%) |
| Jun 2023 | - | $24.03 M(-18.8%) |
| Mar 2023 | - | $29.59 M(+57.5%) |
| Dec 2022 | $18.79 M(-22.5%) | $18.79 M(-17.4%) |
| Sep 2022 | - | $22.76 M(-15.9%) |
| Jun 2022 | - | $27.06 M(-2.9%) |
| Mar 2022 | - | $27.85 M(+14.9%) |
| Dec 2021 | $24.24 M(+44.0%) | $24.24 M(+1.2%) |
| Sep 2021 | - | $23.95 M(+20.1%) |
| Jun 2021 | - | $19.94 M(+54.5%) |
| Mar 2021 | - | $12.91 M(-23.3%) |
| Dec 2020 | $16.84 M(+10.3%) | $16.84 M(+42.6%) |
| Sep 2020 | - | $11.81 M(+4.1%) |
| Jun 2020 | - | $11.35 M(+54.9%) |
| Mar 2020 | - | $7.33 M(-52.0%) |
| Dec 2019 | $15.27 M(+77.6%) | $15.27 M(+53.2%) |
| Sep 2019 | - | $9.97 M(-17.8%) |
| Jun 2019 | - | $12.12 M(+66.5%) |
| Mar 2019 | - | $7.28 M(-15.3%) |
| Dec 2018 | $8.60 M(-36.0%) | $8.60 M(+34.2%) |
| Sep 2018 | - | $6.40 M(-14.0%) |
| Jun 2018 | - | $7.45 M(-11.9%) |
| Mar 2018 | - | $8.45 M(-37.1%) |
| Dec 2017 | $13.43 M | $13.43 M(+51.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $8.90 M(-6.6%) |
| Jun 2017 | - | $9.53 M(-8.8%) |
| Mar 2017 | - | $10.44 M(-8.6%) |
| Dec 2016 | $11.42 M(+117.8%) | $11.42 M(-2.9%) |
| Sep 2016 | - | $11.76 M(+12.8%) |
| Jun 2016 | - | $10.43 M(+30.2%) |
| Mar 2016 | - | $8.01 M(+52.7%) |
| Dec 2015 | $5.25 M(+54.0%) | $5.25 M(+26.0%) |
| Sep 2015 | - | $4.16 M(+5.4%) |
| Jun 2015 | - | $3.95 M(-25.3%) |
| Mar 2015 | - | $5.29 M(+55.2%) |
| Dec 2014 | $3.41 M(+24.0%) | $3.41 M(+43.7%) |
| Sep 2014 | - | $2.37 M(-44.3%) |
| Jun 2014 | - | $4.25 M(+25.8%) |
| Mar 2014 | - | $3.38 M(+23.2%) |
| Dec 2013 | $2.75 M(+36.8%) | $2.75 M(-28.0%) |
| Sep 2013 | - | $3.81 M(-7.1%) |
| Jun 2013 | - | $4.10 M(+104.3%) |
| Mar 2013 | - | $2.01 M(+0.0%) |
| Dec 2012 | $2.01 M(-55.9%) | $2.01 M(+277.4%) |
| Sep 2012 | - | $532.00 K(-84.2%) |
| Jun 2012 | - | $3.37 M(+124.0%) |
| Mar 2012 | - | $1.50 M(-67.0%) |
| Dec 2011 | $4.56 M(+1236.4%) | $4.56 M(+2.8%) |
| Sep 2011 | - | $4.43 M(-18.4%) |
| Jun 2011 | - | $5.44 M(+9115.3%) |
| Mar 2011 | - | $59.00 K(-82.7%) |
| Dec 2010 | $341.00 K(>+9900.0%) | $341.00 K(-67.6%) |
| Sep 2010 | - | $1.05 M(>+9900.0%) |
| Dec 2009 | $0.00 | $0.00 |
FAQ
- What is Pacific Biosciences of California annual accounts receivable?
- What is the all time high annual accounts receivable for Pacific Biosciences of California?
- What is Pacific Biosciences of California annual accounts receivable year-on-year change?
- What is Pacific Biosciences of California quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Pacific Biosciences of California?
- What is Pacific Biosciences of California quarterly accounts receivable year-on-year change?
What is Pacific Biosciences of California annual accounts receivable?
The current annual accounts receivable of PACB is $27.52 M
What is the all time high annual accounts receivable for Pacific Biosciences of California?
Pacific Biosciences of California all-time high annual accounts receivable is $36.62 M
What is Pacific Biosciences of California annual accounts receivable year-on-year change?
Over the past year, PACB annual accounts receivable has changed by -$9.09 M (-24.83%)
What is Pacific Biosciences of California quarterly accounts receivable?
The current quarterly accounts receivable of PACB is $27.52 M
What is the all time high quarterly accounts receivable for Pacific Biosciences of California?
Pacific Biosciences of California all-time high quarterly accounts receivable is $36.62 M
What is Pacific Biosciences of California quarterly accounts receivable year-on-year change?
Over the past year, PACB quarterly accounts receivable has changed by -$1.86 M (-6.33%)